Celebrex Total Knee Arthroplasty Study

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Osteoarthritis, Pain

In brief

This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing elective unilateral primary total knee arthroplasty (TKA) from the pre-operative phase to the management of post total knee replacement pain, and through the 6 weeks of physical therapy and rehabilitation.

Key facts

Study ID

NCT00359151

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

22

Starts

2006-11-01

Expected to finish

2007-07-01

Last updated by the study team

2021-03-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is a male or female 18 years or older with osteoarthritis of the knee scheduled to undergo elective unilateral primary total knee arthroplasty because of OA, performed under a standardized regimen of anesthesia and procedure.

You may not qualify if…

• Subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis) other than osteoarthritis.

Where it is running

• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Englewood, Colorado, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Bellaire, Texas, United States
• Pfizer Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.